New Class of Drugs Blocks Wakefulness Chemical and Offers Relief from Insomnia

Chronic insomnia affects 10-30% of adults globally, impacting daily life and often accompanying other health issues. Emerging treatments include dual orexin receptor antagonist (DORA) drugs, which block wakefulness-promoting neurons with fewer side effects than traditional sleep aids. Other potential therapies include cannabinoids, digital cognitive behavioral therapy, and wearable devices stimulating slow-wave brain activity. Future research aims to develop personalized insomnia treatments based on individual factors, offering new solutions for millions of sufferers.